Determination of class G antibodies to SARS-CoV2 after application of ‘GamCOVID-Vac’ or ‘Sputnik V’ vaccine of National Research Centre for Epidemiology and Microbiology n.a. honorary academician N.F. Gamaleya

2021 ◽  
pp. 36-40
Author(s):  
N. A. Alkhutova ◽  
N. A. Kovyazina ◽  
N. A. Bardysheva ◽  
N. M. Kalinina ◽  
S. S. Alexanin
Keyword(s):  
Immune Response ◽  
Blood Serum ◽  
Interim Analysis ◽  
Protein S ◽  
Research Centre ◽  
Antigenic Determinants ◽  
Igg Antibodies ◽  
Laboratory Examination ◽  
Post Vaccination

We conducted a laboratory examination of 83 people after vaccination against the new coronavirus with the use of the ‘Gam-COVID-Vac’ vaccine of National Research Centre for Epidemiology and Microbiology n.a. honorary academician N.F. Gamaleya (Moscow, Russia), in order to determine the presence of post-vaccination class G antibodies to SARS-CoV-2. The reagent system ‘SARS-CoV-2-IgG – ELISA-BEST’ (Vector-Best Co., Novosibirsk, Russia) was used. According to the manufacturer, the reagent system detects a pool of class G immunoglobulins synthesized to all antigenic determinants of protein S, including the RBD domain, which ensures the specificity of this method for assessing the post-vaccination immune response. The study involved 36 men and 47 women, with an average age of 48.40 ± 1.15 years. An interim analysis of the blood serum of 51 participants 21 days after the first dose of the vaccine showed the presence of IgG antibodies to SARS-CoV-2 in 45 (88.24%) people. After 42 days, all 83 (100%) people were found to have IgG antibodies to SARS-CoV-2 virus. It is advisable to continue the study to assess the dynamics of the level of postvaccinal antibodies for 6 months.

scholarly journals Two SARS-CoV-2 IgG Immunoassays Comparison and Time-Course Profile of Antibodies Response

2020 ◽  
Author(s):  
Ruggero Dittadi ◽  
Haleh Afshar ◽  
Paolo Carraro
Keyword(s):  
Immune Response ◽  
Time Course ◽  
Automated Systems ◽  
Igg Antibodies ◽  
Quantitative Correlation ◽  
Circulating Antibodies

The role of the immune response to SARS-CoV-2 infection is not yet well known, in particular about the persistence of circulating antibodies. The aim of the study is to compare the results of two automated systems for the determination of IgG antibodies against SARS CoV-2 and to assess the time course of the IgG response after the onset of symptoms for a period longer than that evaluated to date. IgG were measured in 98 specimens of 55 subjects with COVID-19 (time from the onset of symptoms from 3 to 109 days) using the automated tests "Abbott SARS-COV-2 IgG" and the "MAGLUMI 2019-nCoV IgG". The two methods had a concordance of 91.8%, but the quantitative correlation showed very dispersed results. All the specimens resulted positive after 17 days from the onset of the synptoms. However, the median concentrations of IgG, after a rapid increase up to about 20 days, quickly decrease to about 15% of the maximum for Maglumi. The same samples measured by Architect showed a quite constant trend up to 80 day, and then an only moderate decline. The titer of IgG against SARS-CoV-2 in patients exposed to COVID-19 may significantly and rapidly decrease, with a different time-course depending on the method used for the determination.

scholarly journals Study of the post-vaccination anti-HBV immune response in the health staff of the Souro SANOU University Hospital in Bobo-Dioulasso.

2019 ◽  
Author(s):  
Yacouba SOURABIE ◽  
Mafama SIRIBIE ◽  
Michel K GOMGNIMBOU ◽  
Macaire S OUEDRAOGO ◽  
Francis Fumoux ◽  
...  
Keyword(s):  
Immune Response ◽  
Hospital Setting ◽  
University Hospital ◽  
Health Staff ◽  
Post Vaccination ◽  
Significant Difference ◽  
B Virus ◽  
Bobo Dioulasso ◽  
Limited Setting

Abstract Background Post immune response again VHB after immunization have been slowly reported in health personal in limited setting country. We aimed to evaluate the post-vaccination immune response against the hepatitis B virus in health personal at CHUSS Bobo-Dioulasso.Methods This was a prospective cohort study that was conducted from March 2014 to January 2015 at CHUSS. Thus, 84 vaccinated subjects were included. Whole blood was collected from each subject for antibody determination. CMIA technology was used for the determination of anti-HBs antibodies. Subjects with a titer of less than 100 mIU / ml were considered non-protective in the hospital setting.Results The average age of the subjects is 40.38 ± 9.82 years. The sex ratio is 2.23. Of these, 47.6% had an Ac titre greater than 100 mIU / ml, and considered very well immunized. Also, 52.4% had an Ac titer less than 100 mIU / ml; and considered as unprotected subject in a hospital setting. Of these, 27.38% had a titer of between 10 and 99 mIU / ml and 30% had a titer of less than 10 mIU / ml. Comparing the different proportions of non-responders by age, we find that there is no statistically significant difference between non-responders aged ≤ 40 years compared to those aged> 40 years (p = 0.8). Comparing the different proportions of non-responders by sex, we find that there is a statistically significant difference between male and female non-responders (p = 0.044).Conclusion We found that about half of the subjects had satisfactory protection, which indicates a good efficacy of SHANVAC B®. Research on immunological non-responders should be pursued to identify possible causes.

Fast and Simple Routine Determination of Bromine by XRF in Wet Blood Serum Microsamples Evaluation of Errors

1991 ◽  
Vol 35 (B) ◽  
pp. 1175-1182
Author(s):  
C. Shenberg ◽  
J. Gilat ◽  
M. Mantel
Keyword(s):  
Detection Limit ◽  
Blood Serum ◽  
Total Error ◽  
Nuclear Research ◽  
Research Centre ◽  
X Rays ◽  
Industrial Workers ◽  
X Ray ◽  
Bromine Concentration

AbstractA specific XRF method, developed at the Soreq Nuclear Research Centre, was applied to the determination of bromine in blood. The method is based on excitation with a Mo X-ray tube and detection of the fluorescent Br K X-rays by a Si (Li) detector. Serum microsamples (300 μL) are counted directly, without drying, for 100 sec, The detection limit obtained under these conditions is 0.6 ppm Br, The overall precision of the method was found to be ±3.1%. The different parameters which contribute to the total error of the method were studied, A survey of the bromine concentration in the blood serum of industrial workers exposed to bromine compounds was carried out.

scholarly journals STRATEGY FOR THE DIAGNOSTICS OF TOXOPLASMOSIS IN DIFFERENT POPULATION GROUPS

2021 ◽  
pp. 29-36
Author(s):  
D.B. Goncharov ◽  
◽  
E.V. Abbazova ◽  
V.A. Kovaleva ◽  
B.I. Maracusha ◽  
...  
Keyword(s):  
Antibody Detection ◽  
Study Group ◽  
Significant Heterogeneity ◽  
Igg Antibodies ◽  
Laboratory Examination ◽  
Population Groups ◽  
Igm Antibodies ◽  
Level Of Invasion ◽  
Iga Antibodies

The analysis of laboratory examination of the population with latent and chronic toxoplasmosis has a number of complexities. Therefore, the search for accurate biomarkers of toxoplasmosis to differentiate the stage of invasion development is very important. From the group of 559 persons, the infection of T. gondii was found in 27,9%. It is shown that a person is more often infected in childhood, teenage years and adolescence, which is marked by the presence of IgM antibodies and high levels of IgG antibodies. It was confirmed that IgA antibodies is an effective marker of reactivation of latent toxoplasmosis. The laboratory determination of toxoplasmosis markers showed a significant heterogeneity of the study group in terms of the level of invasion, depending on age, as well as the possibility to identify the stage and duration of the disease, including reactivation. Keyword: toxoplasmosis, antibody detection, latent invasion, reactivation, immunological diagnostics

MYCOPLASMA AND CHLAMYDIA AS ETHIOLOGICAL FACTORS OF BRONCHIAL ASTHMA IN TERMS OF ETHNOGENESIS

2013 ◽  
Vol 68 (7) ◽  
pp. 57-60
Author(s):  
O. A. Sharavii ◽  
S. V. Smirnova
Keyword(s):  
Immune Response ◽  
Chlamydia Trachomatis ◽  
Blood Serum ◽  
Bronchial Asthma ◽  
Mycoplasma Hominis ◽  
Acute Stage ◽  
Control Group ◽  
Clinical Markers ◽  
Chlamydophila Psittaci ◽  
Asthma Patients

 Aim. The study of the prevalence and clinical peculiarities of Mycoplasmosis and Chlamydiosis in patients with different pathogenic forms of bronchial asthma (BA) taking into account ethnicity of a patient. Subjects and Methods. The research covered 239 subjects – both the Europeoids and the Mongoloids in the city of Krasnoyarsk and the town of Kyzyl, all of them being BA patients of different stages, including acute stage and practically healthy. We had determined antigens Mycoplasma pneumoniae, Mycoplasma hominis, Chlamydophila pneumoniae, Chlamydophila psittaci and Chlamydia trachomatis in smears of mucosa of pharynx and antibodies to these antigens in peripheral blood serum. Results.  We found high frequency of Mycoplasmosis and Chlamydiosis in the inhabitants of Eastern Siberia, BA patients with different pathogenic forms as compared to control group. We had determined ethnic peculiarities of specific immune response: IgM to М. pneumoniae was revealed in the Europoids more frequently than in the Mongoloids, but IgM to С. pneumoniae and to C. trachomatis, C. trachomatis antigens had been revealed more often in the Mongoloids than in the Europoids. We accepted as clinical equivalents of Mycoplasmosis and Chlamydiosis diagnostics the following signs: temperature around 37C (subfebrile temperature), non-intensive but stable coughing with scanty mucous and muco-purulent sputum, dyspnea of mixed character. Conclusions. Mycoplasma and Chlamydia are meaningful etiologic factors of bronchial asthma. We have found the peculiarities of immune response depending on ethnicity of a patient (ethnic belonging). Clinical markers of Mycoplasmosis and Chlamydiosis should be taken into account in bronchial asthma in order to provide diagnostics timely as well as eradication of infection agents. Because of insufficient knowledge of problem of bronchial asthma related to contamination with Мycoplasma and Chlamydia we put the goal to study the frequency of Mycoplasmosis and Chlamydiosis occurrence in bronchial asthma patients and determine the characteristics clinical course of diseases. We defined antigens Мycoplasma pneumoniae, Мycoplasma hominis, Chlamydophila pneumoniaе, Chlamydophila psittaci, Chlamydia trachomatis in smears of oropharynx mucosa and antibodies to them in blood serum. 

Polarographic study of hydrolysis of [8-lysine]vasopressin and its derivatives with blood serum of pregnant women

1980 ◽  
Vol 45 (4) ◽  
pp. 1099-1108 ◽  
Author(s):  
Mikuláš Chavko ◽  
Michal Bartík ◽  
Evžen Kasafírek
Keyword(s):  
Blood Serum ◽  
Pregnant Women ◽  
Degree Of Hydrolysis ◽  
Polarographic Study ◽  
Ph Optimum ◽  
Lysine Vasopressin ◽  
Rate Of Hydrolysis ◽  
Hydrolysis Of ◽  
Vasopressin Analogues

A polarographic study of the hydrolysis of [8-lysine]vasopressin and some hormonogens of the vasopressin series with the blood serum of women in the last week of pregnancy was studied. The dependence of hydrolysis on pH (pH optimum: 7.4-7.50, substrate concentration (Km 1.2 . 10-5M), pH stability and thermal stability were determined. The rate of hydrolysis of individual vasopressin analogues decreases in the order: [8-lysine]vasopressin > Nα-glycyl-prolyl[8-lysine]-vasopressin > Nα-leucyl-[8-lysine]vasopressin > Nα-alanyl-[8-lysine]vasopressin > Nα-phenyl alanyl-[8-lysine]vasopressin > Nα-diglycyl-[8-lysine]vasopressin > Nα-prolyl-[8-lysine]vasopressin > Nα-triglycyl-[8-lysine]vasopressin > Nα-sarcosyl-glycyl-[8-lysine]vasopressin. The degree of hydrolysis gradually increases to a multiple with the length of the pregnancy in consequence of the presence of oxytocine. However, vasopressin is also hydrolysed to a small extent with the enzymes from the blood sera of non-pregnant women. Under similar analytical conditions oxytocin was not hydrolysed with the sera of non-pregnant women and therefore oxytocin is a more suitable substrate than vasopressin for polarographic determination of serum oxytocinase.

scholarly journals The Analysis of Live-Attenuated Piscirickettsia salmonis Vaccine Reveals the Short-Term Upregulation of Innate and Adaptive Immune Genes in Atlantic Salmon (Salmo salar): An In Situ Open-Sea Cages Study

2021 ◽  
Vol 9 (4) ◽  
pp. 703
Author(s):  
Deborah Vargas ◽  
Eva Vallejos-Vidal ◽  
Sebastián Reyes-Cerpa ◽  
Aarón Oyarzún-Arrau ◽  
Claudio Acuña-Castillo ◽  
...  
Keyword(s):  
Immune Response ◽  
Atlantic Salmon ◽  
Salmo Salar ◽  
Cellular Response ◽  
Short Term ◽  
Live Attenuated Vaccine ◽  
Gene Markers ◽  
Post Vaccination ◽  
Atlantic Salmon Salmo Salar ◽  
Piscirickettsia Salmonis

Piscirickettsia salmonis, the etiological agent of the Salmon Rickettsial Septicemia (SRS), is one the most serious health problems for the Chilean salmon industry. Typical antimicrobial strategies used against P. salmonis include antibiotics and vaccines, but these applications have largely failed. A few years ago, the first attenuated-live vaccine against SRS (ALPHA JECT LiVac® SRS vaccine) was released to the market. However, there is no data about the agents involved in the activation of the immune response induced under field conditions. Therefore, in this study we evaluated the expression profile of a set of gene markers related to innate and adaptive immunity in the context of a cellular response in Atlantic salmon (Salmo salar) reared under productive farm conditions and immunized with a live-attenuated vaccine against P. salmonis. We analyzed the expression at zero, 5-, 15- and 45-days post-vaccination (dpv). Our results reveal that the administration of the attenuated live SRS LiVac vaccine induces a short-term upregulation of the cellular-mediated immune response at 5 dpv modulated by the upregulation of ifnα, ifnγ, and the cd4 and cd8α T cell surface markers. In addition, we also registered the upregulation of il-10 and tgfβ. Altogether, the results suggest that a balanced activation of the immune response took place only at early times post-vaccination (5 dpv). The scope of this short-term upregulation of the cellular-mediated immune response against a natural outbreak in fish subjected to productive farm conditions deserves further research.

scholarly journals The Koala Immune Response to Chlamydial Infection and Vaccine Development—Advancing Our Immunological Understanding

Animals ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 380
Author(s):  
Bonnie L Quigley ◽  
Peter Timms
Keyword(s):  
Immune Response ◽  
Chlamydial Infection ◽  
Vaccine Development ◽  
Interleukin 17 ◽  
Phascolarctos Cinereus ◽  
Post Vaccination ◽  
Research Systems ◽  
Cytokine Levels ◽  
Nucleic Acid Assay ◽  
Immunological Research

Chlamydia is a significant pathogen for many species, including the much-loved Australian marsupial, the koala (Phascolarctos cinereus). To combat this situation, focused research has gone into the development and refinement of a chlamydial vaccine for koalas. The foundation of this process has involved characterising the immune response of koalas to both natural chlamydial infection as well as vaccination. From parallels in human and mouse research, it is well-established that an effective anti-chlamydial response will involve a balance of cell-mediated Th1 responses involving interferon-gamma (IFN-γ), humoral Th2 responses involving systemic IgG and mucosal IgA, and inflammatory Th17 responses involving interleukin 17 (IL-17) and neutrophils. Characterisation of koalas with chlamydial disease has shown increased expression within all three of these major immunological pathways and monitoring of koalas’ post-vaccination has detected further enhancements to these key pathways. These findings offer optimism that a chlamydial vaccine for wider distribution to koalas is not far off. Recent advances in marsupial genetic knowledge and general nucleic acid assay technology have moved koala immunological research a step closer to other mammalian research systems. However, koala-specific reagents to directly assay cytokine levels and cell-surface markers are still needed to progress our understanding of koala immunology.

scholarly journals The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection—A Systematic Review

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1339
Author(s):  
Kristoffer Juul Nielsen ◽  
Kathrine Kronberg Jakobsen ◽  
Jakob Schmidt Jensen ◽  
Christian Grønhøj ◽  
Christian Von Buchwald
Keyword(s):  
Cohort Study ◽  
Oropharyngeal Cancer ◽  
Hpv Infection ◽  
Case Control ◽  
Igg Antibodies ◽  
Hpv Vaccines ◽  
Case Control Studies ◽  
Cross Sectional ◽  
Post Vaccination ◽  
Cross Sectional Studies

Human papillomavirus (HPV) imposes an increased risk of developing cervical, anal and oropharyngeal cancer. In the Western world, HPV infection is currently the major cause of oropharyngeal cancer. The effectiveness of HPV vaccines for oral or oropharyngeal HPV infection is yet to be determined. This study conducted a systematic literature search in Pubmed and Embase. Studies investigating the impact of HPV vaccines on oral or oropharyngeal HPV infection were enrolled. This review reports the relative prevention percentage (RPP), including a risk of bias assessment as well as a quality assessment study. Nine studies were included (48,777 participants): five cross-sectional studies; one randomized community trial study (RCT); one longitudinal cohort study; and two case-control studies. A significant mean RPP of 83.9% (66.6–97.8%) was calculated from the cross-sectional studies, 82.4% in the included RCT and 83% in the longitudinal cohort study. Further, two case-control studies that measured antibody response in participants immunized with HPV vaccines were included. Respectively, 100% and 93.2% of participants developed HPV-16 Immunoglobulin G (IgG) antibodies in oral fluids post-vaccination. Analysis of the studies identified a significant decrease in vaccine-type oral or oropharyngeal HPV infections in study participants immunized with HPV vaccines across study designs and heterogenous populations. Further, a significant percentage of participants developed IgG antibodies in oral fluid post-vaccination.

Sign in / Sign up

Export Citation Format

Share Document